SCHEMBL4948201

SCHEMBL4948201

COC(=O)c1ccc(C#C[Se]c2cc(OCc3ccc(C(C)(C)C)cc3)c3c(c2)C(C)(C)CCC3(C)C)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.39
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
MAPT P10636 3/20 0.38
RAB9A P51151 3/20 0.38
LMNA P02545 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CYP26A1 O43174 2/20 0.37
RXRA P19793 2/20 0.37
RXRB P28702 2/20 0.37
NR4A2 P43354 2/20 0.37
SMN1; SMN2 Q16637 3/20 0.36
RXRG P48443 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
NR4A1 P22736 1/20 0.35
NR4A3 Q92570 1/20 0.35
MRGPRX4 Q96LA9 3/20 0.35
EGFR P00533 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4946950 0.93 MRGPRX4 (0.42) CYP3A4MAPTRAB9ALMNAL3MBTL1
SCHEMBL4946268 0.92 RXRA (0.47) CYP3A4RAB9AL3MBTL1CYP26A1RXRA
SCHEMBL4944815 0.91 MAPT (0.41) CYP3A4MAPTRAB9ALMNAL3MBTL1
SCHEMBL4945300 0.90 CYP3A4 (0.41) CYP3A4MAPTRAB9ALMNAL3MBTL1
SCHEMBL4946956 0.90 MAPT (0.41) CYP3A4MAPTRAB9ALMNAL3MBTL1
SCHEMBL4946310 0.90 RAB9A (0.44) CYP3A4MAPTRAB9ALMNAL3MBTL1
SCHEMBL4946301 0.88 CYP3A4 (0.39) CYP3A4MAPTRAB9ALMNAL3MBTL1
SCHEMBL4946321 0.87 MAPT (0.40) CYP3A4MAPTRAB9ALMNAL3MBTL1
SCHEMBL4942407 0.87 CYP3A4 (0.40) CYP3A4MAPTRAB9ALMNAL3MBTL1
SCHEMBL4945312 0.87 MRGPRX4 (0.43) CYP3A4MAPTRAB9ALMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1513803-B1 LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS GALDERMA RES & DEV (FR) 2008-06-18 EP disclosed
US-7326803-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-02-05 US disclosed
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof RARA, RARB, RARG CYP3A4 2257/4885CA1 4382/4885CA2 3656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.